Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece

Completed

• Conditions: Diabetic Macular Edema

• Registration Number: NCT05683912
• Lead Sponsor: University of Athens

Brief Summary

ADMIRE was a prospective, observational cohort study of patients with diabetic macular edema (DME). Efficacy was assessed by change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to months 12, 24 and 36 after treatment with intravitreal aflibercept in treatment-naïve patients and previously treated patients. Safety was evaluated by recording any patients-reported events.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-09-01
• Primary Completion: 2021-09-01
• Status Verified: 2022-12
• Study Completion: 2022-12-15
• Study First Submitted: 2022-12-27
• Study First Submitted QC: 2022-12-27
• Last Update Submitted: 2022-12-27
• Study First Posted: 2023-01-13
• Last Update Posted: 2023-01-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Patients with DM, able to give written informed consent Patients with DME>320 μm, who need treatment

Exclusion Criteria

Patients with other retinal diseases than DME Intraocular surgery within the last 6 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in best-corrected visual acuity	12 months

Trial Locations

Locations (1)

University of Athens; 🇬🇷 Athens, Greece